Sartorius AG

euro adhoc: Sartorius AG
quarterly or semiannual financial statement
Figures for the First Quarter of 2008 Sales revenue rose 3.8% (currency-adjusted: up 7.7%) | Currency-adjusted order intake up 3.4% | EBITA at EUR12.2 million up from the ...

@@start.t1@@--------------------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc. The issuer is responsible   for the content of this announcement. --------------------------------------------------------------------------------@@end@@

22.04.2008

To ensure the best possible comparability, the first-quarter figures of 2007 are shown on a pro forma basis and adjusted for extraordinary expenses.

Within the first three months of 2008, the Sartorius Group increased sales revenue by 3.8% to EUR149.2 million (Q1 2007: EUR143.6 mn). Currency-adjusted consolidated sales revenue climbed 7.7%. The Biotechnology Division's sales revenue rose 5.4% (currency-adjusted: +9.5%) to EUR90.6 (Q1 2007: EUR85.9 mn). Sales revenue for the Mechatronics Division grew 1.5% (currency-adjusted: +5.1%) to EUR58.6 million (Q1 2007: EUR57.7 mn).

At EUR162.5 million, order intake was higher than sales revenue and thus at the high level of the year-earlier quarter (EUR162.9 mn). On the basis of constant currencies, order intake rose 3.4%. The difference between sales revenue and order intake essentially resulted from the fluctuations in the equipment business of the Biotechnology Division. The Division's order intake was EUR97.6 million (Q1 2007: EUR99.1 million), which corresponds to a decline of 1.5% or a currency-adjusted increase of 2.2%. The value of orders for the Mechatronics Division rose 1.8% or by a currency-adjusted rate of 5.3%.

First-quarter operating earnings (earnings before interest, taxes and amortization = EBITA) increased from EUR11.8 million to EUR12.2 million. At 8.2%, the EBITA margin remained unchanged compared to the year-earlier figure. If the EBITA margin had been calculated based on the previous year's exchange rates, it would have increased to more than 9%. EBITA for the Biotechnology Division rose from EUR8.4 million to EUR9.1; for the Mechatronics Division, EBITA at EUR3.1 million was below the year-earlier figure of EUR3.4 million. Net profit after minority interest was EUR3.2 million (Q1 2007: EUR3.5 million); earnings per share (excluding the two non-cash items of amortization and interest on share price warrants granted) were EUR0.25 (Q1 2007: EUR0.26).

For the full fiscal year of 2008, the Sartorius Group is continuing to aim at achieving sales revenue growth of more than 9% in constant currencies. Based on this anticipated sales revenue and on an average exchange rate of 1.40 USD/EUR, the Group is planning to increase the EBITA margin to approx. 12%.

|EUR in millions                         |Q1 2008 |Q1 2007    |Change        |
|(unless otherwise specified)    |            |pro forma |in %          |
|                                                 |            |                |                 |
|Sartorius Group                         |            |                |                 |
|Sales revenue                            |149.2    |143.6        |+3.8 (+7.7)|
|Order intake                              |162.5    |162.9        |-0.2 (+3.4)|
|EBITA 1)                                    |12.2      |11.8         |+3.7          |
|Net profit for the period 1)2) |4.2        |4.4          |-2.9          |
|Earnings per share 1)2) in EUR |0.25      |0.26         |-2.9          |
|                                                 |            |                |                 |
|Biotechnology Division              |            |                |                 |
|Sales revenue                            |90.6      |85.9         |+5.4 (+9.5)|
|Order intake                              |97.6      |99.1         |-1.5 (+2.2)|
|EBITA 1)                                    |9.1        |8.4          |+8.5          |
|                                                 |            |                |                 |
|Mechatronics Division                |            |                |                 |
|Sales revenue                            |58.6      |57.7         |+1.5 (+5.1)|
|Order intake                              |64.9      |63.8         |+1.8 (+5.3)|
|EBITA 1)                                    |3.1        |3.4          |-7.9          |

in parentheses: currency-adjusted 1) for 2007 underlying 2) excluding non-cash amortization and, for 2008, additionally excluding non-cash interest expenses for share price warrants

Dr. Joachim Kreuzburg, CEO of Sartorius, will discuss the quarterly results for Sartorius with analysts and investors in a teleconference at 4:30 p.m. CET following today's Annual Shareholder Meeting. You may dial into this teleconference starting at 4:15 p.m. CET at the following numbers:

Germany: +49 (0)69 5007 1316; France: +33 (0)1 70 99 42 99; UK: +44 (0)20 7806 1968; USA: +1 718 354 1387.

The dial-in code is 3601455;

to view the webcast, log onto www.livemeeting.com/cc/premconfeurope/j oin?id=3601455&role=attend&pw=pw7076

-----------------------

@@start.t2@@end of announcement                                                 euro adhoc
--------------------------------------------------------------------------------@@end@@

ots Originaltext: Sartorius AG
Im Internet recherchierbar: http://www.presseportal.ch

Further inquiry note:
Andreas Wiederhold
Treasury & Investor Relations
Telefon: +49 (0)551 308-1668
E-Mail: andreas.wiederhold@sartorius.com

Branche: Biotechnology
ISIN:      DE0007165607
WKN:        716560
Index:    CDAX, Prime All Share, Technologie All Share
Börsen:  Börse Frankfurt / regulated dealing/prime standard
              Börse Berlin / free trade
              Börse Hamburg / free trade
              Börse Stuttgart / free trade
              Börse Düsseldorf / free trade
              Börse Hannover / free trade
              Börse München / free trade



Weitere Meldungen: Sartorius AG

Das könnte Sie auch interessieren: